← SynDRA
VABORBACTAM
SynDRA canonical compound SYN0038085 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | LACTB |
|---|
| Mechanism of action | beta lactamase inhibitor |
|---|
All known targets
- LACTB
- Stap-coc blaZ
- blaKPC-2
Mechanisms of action (all sources)
- beta lactamase inhibitor
- Inhibitor
Drug classes
- Anti-Bacterial Agents
- Anti-Infective Agents
- beta-Lactamase Inhibitors
- Enzyme Inhibitors
- beta Lactamase Inhibitors
- beta Lactamase Inhibitor
ATC classes
- OTHER BETA-LACTAM ANTIBACTERIALS
Cross-references
Synonyms
- RPX 7009
- RPX7009
- RPX-7009
- Vaborbactam component of carbavance
- Vaborbactam component of vabomere
- UNII-1C75676F8V
- 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid
- CHEMBL3317857
- 1C75676F8V
- 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid
- Vaborbactam [INN]
- Vaborbactam. RPX7009
- Vaborbactam (USAN/INN)
- Vaborbactam [USAN:INN]
- SCHEMBL620289
- GTPL10871
- Vabomere (vaborbactam + meropenem)
- EX-A2589
- BDBM50089084
- MFCD28502176
- AKOS032961376
- CS-6445
- DB12107
- SB17184
- 1,2-Oxaborinane-6-acetic acid, 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-, (3R,6S)-
- compound 9f [PMID: 25782055]
- NCGC00510003-01
- HY-19930
- 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-
- D10998
- Q27252228
- {(3R,6S)-2-hydroxy-3-[(thiophen-2-ylacetyl)amino]-1,2-oxaborinan-6-yl}acetic acid
- 1,2-Oxaborinane-6-acetic acid
- VABOMERE COMPONENT VABORBACTAM
- CARBAVANCE COMPONENT VABORBACTAM
- vaborbactamum
- RefChem:901532
- DTXCID801513270
Reported adverse events
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Headache
- Nausea
- Phlebitis
- Pyrexia
- Infusion site reaction
- Aspartate aminotransferase
- Death
- Eosinophilia
- Hypersensitivity
- Rhabdomyolysis
Look up VABORBACTAM in the interactive SynDRA portal →